A new editorial was published in Volume 12 of Oncoscience on May 2, 2025, titled "Immune checkpoint inhibitors and myocarditis: Lessons from a nationwide cohort study." ...

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the ...

Personalized medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

"Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial" was originally created and published by ...

Researchers found a significant tradeoff between harms and benefits for patients who received an ICI plus chemotherapy in the first-line setting.

Melanoma care varies by stage, with early cases being treated with surgery, whereas advanced disease often requires ...

Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.

Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression ...